Leonteq Securities AG Makes New $3.28 Million Investment in Bristol Myers Squibb Company $BMY

Leonteq Securities AG acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 60,834 shares of the biopharmaceutical company’s stock, valued at approximately $3,281,000.

Several other hedge funds also recently made changes to their positions in the company. ABN Amro Investment Solutions grew its holdings in shares of Bristol Myers Squibb by 307.7% during the fourth quarter. ABN Amro Investment Solutions now owns 98,319 shares of the biopharmaceutical company’s stock worth $5,303,000 after purchasing an additional 74,202 shares during the last quarter. Rathbones Group PLC grew its holdings in shares of Bristol Myers Squibb by 5.9% during the fourth quarter. Rathbones Group PLC now owns 32,154 shares of the biopharmaceutical company’s stock worth $1,734,000 after purchasing an additional 1,795 shares during the last quarter. Reliant Investment Partners LLC purchased a new position in shares of Bristol Myers Squibb during the fourth quarter worth about $203,000. IFP Advisors Inc grew its holdings in shares of Bristol Myers Squibb by 57.5% during the fourth quarter. IFP Advisors Inc now owns 49,476 shares of the biopharmaceutical company’s stock worth $2,669,000 after purchasing an additional 18,060 shares during the last quarter. Finally, Providence Wealth Advisors LLC grew its holdings in shares of Bristol Myers Squibb by 8.5% during the fourth quarter. Providence Wealth Advisors LLC now owns 32,445 shares of the biopharmaceutical company’s stock worth $1,712,000 after purchasing an additional 2,543 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a strategic agreement with Anthropic to make Claude Enterprise available across its global operations, including more than 30,000 employees, with use cases spanning research, drug development, manufacturing, and commercial functions. The deal may help accelerate discovery and lower operating friction. Article Title
• Positive Sentiment: Multiple reports confirmed Bristol Myers Squibb is deploying Anthropic’s Claude AI tools to speed up drug discovery and broaden AI adoption across the company, reinforcing the market’s view that BMY is investing in productivity-enhancing technology. Article Title
• Positive Sentiment: Tempus AI also announced an expanded collaboration with Bristol Myers Squibb to improve clinical trial design and increase the probability of success across five development programs, which supports the company’s pipeline execution story. Article Title
• Neutral Sentiment: Coverage pieces from Seeking Alpha, Yahoo Finance, and Zacks indicate BMY is a closely watched stock right now, but these items appear more descriptive than fundamentally new. Article Title
• Neutral Sentiment: Recent commentary also continues to focus on pipeline hopes, patent risks, and valuation moves, which keep investor attention on long-term execution rather than near-term financial results. Article Title

Analyst Ratings Changes

BMY has been the topic of a number of research reports. Barclays initiated coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price target on the stock. Wells Fargo & Company reissued an “outperform” rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Morgan Stanley reissued an “underweight” rating and set a $40.00 price target on shares of Bristol Myers Squibb in a report on Friday, February 6th. Piper Sandler reissued an “overweight” rating and set a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Finally, UBS Group reissued a “buy” rating and set a $70.00 price target on shares of Bristol Myers Squibb in a report on Friday, March 6th. Eight equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $58.45 on Thursday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The business’s 50-day moving average price is $58.48 and its 200 day moving average price is $55.73. The firm has a market cap of $119.37 billion, a P/E ratio of 16.42, a P/E/G ratio of 0.17 and a beta of 0.26. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter in the previous year, the company earned $1.80 EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.